Nohla Therapeutics Receives FDA Fast Track Designation for Dilanubicel for Allogeneic Cord Blood Transplant Patients
August 06, 2018 13:00 ET | Nohla Therapeutics
SEATTLE, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
Nohla Therapeutics Announces Hiring of Dr. Sarah Noonberg as Chief Medical Officer and Appointment of Dr. Colleen Delaney as Chief Scientific Officer
July 30, 2018 13:00 ET | Nohla Therapeutics
SEATTLE, July 30, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
Nohla Therapeutics Receives FDA Orphan Drug Designation for Dilanubicel for Hematopoietic Stem Cell Transplant Patients
July 16, 2018 13:30 ET | Nohla Therapeutics
SEATTLE, July 16, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
Nohla Therapeutics Announces Second Closing of $56 Million Series B Financing
July 11, 2018 16:00 ET | Nohla Therapeutics
SEATTLE, July 11, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
Nohla Announces Presentation of Dilanubicel (NLA101) Data at EHA Annual Meeting Showcasing Excellent Long-term Survival Outcomes
June 15, 2018 11:30 ET | Nohla Therapeutics
SEATTLE, June 15, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
Nohla Receives EMA PRIME Designation for Dilanubicel (NLA101) to Treat Hematopoietic Stem Cell Transplant Patients
June 06, 2018 13:00 ET | Nohla Therapeutics
SEATTLE, June 06, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
Nohla Announces EHA Abstract Acceptance on Dilanubicel (NLA101) Off-the-Shelf Cell Therapy Showing Excellent Long-term Survival Outcomes
May 17, 2018 13:00 ET | Nohla Therapeutics
SEATTLE, May 17, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases,...
Nohla Therapeutics Announces Closing of $45 Million Series B Financing
May 15, 2018 13:00 ET | Nohla Therapeutics
SEATTLE, May 15, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases,...
Nohla Therapeutics Announces Hiring of Gary Christianson as Chief Operating Officer
April 23, 2018 16:00 ET | Nohla Therapeutics
SEATTLE, April 23, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics Inc. (Nohla), a clinical stage biopharmaceutical company focused on the development of universal, off-the-shelf cell therapies to treat...
Nohla Therapeutics Selects Advanced Therapies Business Unit of WuXi AppTec To Manufacture Universal Donor Cell Therapies
March 21, 2018 07:00 ET | Nohla Therapeutics
SEATTLE and PHILADELPHIA, March 21, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal donor cell therapies for patients with hematologic malignances and other critical...